Belo Sun Mining Appoints New Board Member
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy BSX?
Source: Yahoo Finance
- New Board Member: Belo Sun Mining Corp. announces the nomination of Benjamin Buckingham to the Board, replacing Jack Lunnon who stepped down due to internal transitions, indicating a strategic adjustment in the company's governance structure.
- Investment Background: Buckingham brings over 10 years of experience in metals and mining investment, having served as Vice President of Investments at La Mancha since 2020, where he evaluates investment opportunities and executes transactions, likely enhancing the company's investment decision-making capabilities.
- Project Advancement Support: His appointment is expected to provide crucial corporate development and project financing support for Belo Sun's Volta Grande Project, aiding the company's mining development strategy in Brazil.
- Continued Involvement: Although Lunnon has resigned from the Board, he will remain as Chief Technical Officer of La Mancha, ensuring ongoing technical and strategic support for Belo Sun, reflecting La Mancha's long-term commitment to the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 72.210
Low
94.00
Averages
108.14
High
132.00
Current: 72.210
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Positioned for Growth Amid Aging Population
- Aging Population Opportunity: Research from the WHO indicates that by 2050, the proportion of people aged 60 and older will rise to 22%, presenting significant market opportunities for Boston Scientific, particularly in the medical device sector.
- Product Line Expansion: Boston Scientific is enhancing its product portfolio in stroke treatment and prevention through the acquisitions of Penumbra and Silk Road Medical, which is expected to further increase its market share among elderly patients.
- Financial Performance and Market Reaction: Despite achieving double-digit revenue and profit growth in its recent earnings report, the conservative guidance for 2026 sales growth led to a stock price drop of over 17%, making the current stock price appear relatively cheap.
- Valuation Attractiveness: With a forward P/E ratio slightly above 22 and a five-year PEG ratio of 0.85, Boston Scientific is considered undervalued, especially given its consistent growth, attracting investor interest.
See More
Belo Sun Mining Appoints New Board Member
- New Board Member: Belo Sun Mining Corp. announces the nomination of Benjamin Buckingham to the Board, replacing Jack Lunnon who stepped down due to internal transitions, indicating a strategic adjustment in the company's governance structure.
- Investment Background: Buckingham brings over 10 years of experience in metals and mining investment, having served as Vice President of Investments at La Mancha since 2020, where he evaluates investment opportunities and executes transactions, likely enhancing the company's investment decision-making capabilities.
- Project Advancement Support: His appointment is expected to provide crucial corporate development and project financing support for Belo Sun's Volta Grande Project, aiding the company's mining development strategy in Brazil.
- Continued Involvement: Although Lunnon has resigned from the Board, he will remain as Chief Technical Officer of La Mancha, ensuring ongoing technical and strategic support for Belo Sun, reflecting La Mancha's long-term commitment to the company.
See More
Aging Population Presents Opportunities for Boston Scientific
- Market Opportunity: Research from the World Health Organization indicates that the proportion of people aged 60 and older will rise from 12% to 22% by 2050, presenting significant market opportunities for medical device manufacturers, particularly Boston Scientific.
- Product Line Expansion: Boston Scientific's Watchman heart implants, launched in 2015, have successfully reduced stroke risks in elderly patients, further solidifying its leadership position in the medical field for older patients.
- Acquisition Strategy: The company agreed to acquire Penumbra for approximately $14.5 billion, focusing on thrombectomy devices, which enhances its product portfolio in stroke prevention, while also planning to acquire Silk Road Medical in 2024 to further expand its market presence.
- Financial Performance: Despite achieving double-digit revenue and profit growth in its latest earnings report, management's guidance for 2026 net sales growth of only 10.5% to 11.5% led to a stock price drop of over 17%, making its current valuation appear relatively cheap.
See More
Investigation into Boston Scientific for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Boston Scientific and its executives have engaged in securities fraud or other unlawful business practices, which could lead to significant losses for investors.
- Disappointing Earnings Report: On February 4, 2026, Boston Scientific released its Q4 2025 financial results, revealing lower-than-expected sales in its electrophysiology division, raising concerns about the company's future performance.
- Stock Price Plunge: Following the earnings report, Boston Scientific's stock price fell by $16.12, or 17.6%, closing at $75.50 on February 4, 2026, reflecting investors' pessimism regarding the company's outlook.
- Potential Legal Consequences: The investigation may lead to a class action lawsuit against Boston Scientific, and if misconduct is confirmed, it could have profound implications for the company's reputation and financial health.
See More
Boston Scientific Initiates Recall of AXIOS Stents Due to Serious Complications
- Product Recall: Boston Scientific has initiated a recall of AXIOS stents and Electrocautery-Enhanced Delivery Systems due to deployment complications linked to 167 serious injuries and three deaths, prompting an immediate halt to their use and distribution.
- FDA Notification: In compliance with the U.S. Food and Drug Administration (FDA), the company notified affected customers on December 19, 2025, advising them to cease using specific devices and to remove remaining inventory to ensure patient safety.
- Risk Assessment: The recall stems from increased reports of complications during stent deployment and expansion, which may prolong procedures and necessitate device replacement, thereby elevating surgical risks for patients.
- Follow-Up Care: Despite the issues, patients with successfully implanted AXIOS stents can continue standard follow-up care, with Boston Scientific emphasizing that the stents should only be used in accordance with their approved Instructions for Use.
See More
Penumbra Reports Strong 2025 Financial Results
- Significant Revenue Growth: Total revenue for Q4 2025 reached $385.4 million, a 22.1% increase from Q4 2024, with the U.S. market contributing 77.6%, indicating strong domestic performance.
- Strong Product Sales: Sales of global thrombectomy products amounted to $254.7 million, up 15.7%, primarily driven by a 12.4% increase in the U.S. market, reflecting sustained demand in key product lines.
- Improved Gross Margin: The gross margin for Q4 2025 was 68.0%, up from 66.8% in Q4 2024, attributed to product mix optimization and enhanced production efficiency, signaling potential future profitability improvements.
- Controlled Operating Expenses: Although R&D expenses slightly increased to $21.8 million, total operating expenses as a percentage of revenue decreased to 52.6%, demonstrating the company's ability to effectively manage costs during expansion.
See More
Boston Scientific Positioned for Growth Amid Aging Population
- Aging Population Opportunity: Research from the WHO indicates that by 2050, the proportion of people aged 60 and older will rise to 22%, presenting significant market opportunities for Boston Scientific, particularly in the medical device sector.
- Product Line Expansion: Boston Scientific is enhancing its product portfolio in stroke treatment and prevention through the acquisitions of Penumbra and Silk Road Medical, which is expected to further increase its market share among elderly patients.
- Financial Performance and Market Reaction: Despite achieving double-digit revenue and profit growth in its recent earnings report, the conservative guidance for 2026 sales growth led to a stock price drop of over 17%, making the current stock price appear relatively cheap.
- Valuation Attractiveness: With a forward P/E ratio slightly above 22 and a five-year PEG ratio of 0.85, Boston Scientific is considered undervalued, especially given its consistent growth, attracting investor interest.
See More
Belo Sun Mining Appoints New Board Member
- New Board Member: Belo Sun Mining Corp. announces the nomination of Benjamin Buckingham to the Board, replacing Jack Lunnon who stepped down due to internal transitions, indicating a strategic adjustment in the company's governance structure.
- Investment Background: Buckingham brings over 10 years of experience in metals and mining investment, having served as Vice President of Investments at La Mancha since 2020, where he evaluates investment opportunities and executes transactions, likely enhancing the company's investment decision-making capabilities.
- Project Advancement Support: His appointment is expected to provide crucial corporate development and project financing support for Belo Sun's Volta Grande Project, aiding the company's mining development strategy in Brazil.
- Continued Involvement: Although Lunnon has resigned from the Board, he will remain as Chief Technical Officer of La Mancha, ensuring ongoing technical and strategic support for Belo Sun, reflecting La Mancha's long-term commitment to the company.
See More
Aging Population Presents Opportunities for Boston Scientific
- Market Opportunity: Research from the World Health Organization indicates that the proportion of people aged 60 and older will rise from 12% to 22% by 2050, presenting significant market opportunities for medical device manufacturers, particularly Boston Scientific.
- Product Line Expansion: Boston Scientific's Watchman heart implants, launched in 2015, have successfully reduced stroke risks in elderly patients, further solidifying its leadership position in the medical field for older patients.
- Acquisition Strategy: The company agreed to acquire Penumbra for approximately $14.5 billion, focusing on thrombectomy devices, which enhances its product portfolio in stroke prevention, while also planning to acquire Silk Road Medical in 2024 to further expand its market presence.
- Financial Performance: Despite achieving double-digit revenue and profit growth in its latest earnings report, management's guidance for 2026 net sales growth of only 10.5% to 11.5% led to a stock price drop of over 17%, making its current valuation appear relatively cheap.
See More
Investigation into Boston Scientific for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Boston Scientific and its executives have engaged in securities fraud or other unlawful business practices, which could lead to significant losses for investors.
- Disappointing Earnings Report: On February 4, 2026, Boston Scientific released its Q4 2025 financial results, revealing lower-than-expected sales in its electrophysiology division, raising concerns about the company's future performance.
- Stock Price Plunge: Following the earnings report, Boston Scientific's stock price fell by $16.12, or 17.6%, closing at $75.50 on February 4, 2026, reflecting investors' pessimism regarding the company's outlook.
- Potential Legal Consequences: The investigation may lead to a class action lawsuit against Boston Scientific, and if misconduct is confirmed, it could have profound implications for the company's reputation and financial health.
See More
Boston Scientific Initiates Recall of AXIOS Stents Due to Serious Complications
- Product Recall: Boston Scientific has initiated a recall of AXIOS stents and Electrocautery-Enhanced Delivery Systems due to deployment complications linked to 167 serious injuries and three deaths, prompting an immediate halt to their use and distribution.
- FDA Notification: In compliance with the U.S. Food and Drug Administration (FDA), the company notified affected customers on December 19, 2025, advising them to cease using specific devices and to remove remaining inventory to ensure patient safety.
- Risk Assessment: The recall stems from increased reports of complications during stent deployment and expansion, which may prolong procedures and necessitate device replacement, thereby elevating surgical risks for patients.
- Follow-Up Care: Despite the issues, patients with successfully implanted AXIOS stents can continue standard follow-up care, with Boston Scientific emphasizing that the stents should only be used in accordance with their approved Instructions for Use.
See More
Penumbra Reports Strong 2025 Financial Results
- Significant Revenue Growth: Total revenue for Q4 2025 reached $385.4 million, a 22.1% increase from Q4 2024, with the U.S. market contributing 77.6%, indicating strong domestic performance.
- Strong Product Sales: Sales of global thrombectomy products amounted to $254.7 million, up 15.7%, primarily driven by a 12.4% increase in the U.S. market, reflecting sustained demand in key product lines.
- Improved Gross Margin: The gross margin for Q4 2025 was 68.0%, up from 66.8% in Q4 2024, attributed to product mix optimization and enhanced production efficiency, signaling potential future profitability improvements.
- Controlled Operating Expenses: Although R&D expenses slightly increased to $21.8 million, total operating expenses as a percentage of revenue decreased to 52.6%, demonstrating the company's ability to effectively manage costs during expansion.
See More
